Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track KRSA with free AI briefings, catalyst countdowns, and dilution alerts.

KRSA · Korsana Biosciences, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$456.2M Cash on Hand
56.7mo Cash Runway
Follow KRSA by email Get an email when KRSA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about KRSA, unsubscribe in one click. Privacy

📣 What KRSA Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

💰 Cash Runway & Dilution Risk

KRSA holds $456.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $24.1M/quarter from operations, an estimated runway of 56.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 10 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when KRSA files for a raise →

👥 Who Owns KRSA

Insiders 33% Other 5%+ holders 53.1% Institutions (30 holders) 13.9% Public and other holders 0%
HolderTypeShares% of sharesAs of
Tomas Kiselak 5%+ holder (13D) 9,106,420 20.00% 2026-09-08
Fairmount Funds Management LLC
Director, 10% owner · +48,445 options
Insider 9,103,729 19.99% 2026-09-08
Venrock Healthcare Capital Partners III, 5%+ holder (13D) 4,552,277 10.00% 2026-09-08
TCG Crossover GP II, LLC 5%+ holder (13G) 4,549,587 9.99% 2026-09-30
Nimish P Shah
Director · +48,445 options
Insider 4,549,585 9.99% 2026-09-08
GENERAL ATLANTIC, L.P. 5%+ holder (13G) 3,201,131 7.03% 2026-09-08
FMR LLC Institution (13G, 5%+) 3,144,797 6.91% 2026-09-30
Wellington Biomedical Innovation Master 5%+ holder (13G) 2,775,788 6.10% 2026-09-09
JPMORGAN CHASE & CO. Institution (13G, 5%+) 2,687,914 5.90% 2026-09-30
Wellington Management Group LLP Institution (13G, 5%+) 2,601,096 5.71% 2026-09-30
JANUS HENDERSON GROUP Ltd. Institution (13G, 5%+) 2,344,819 5.15% 2026-09-30
Peter M Hecht
Director, 10% owner
Insider 910,312 2.00% 2026-07-16

Share count 45,541,358 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full KRSA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for KRSA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.